Expired activity
Please go to the PowerPak homepage and select a course.

Naloxone and Other Harm-Reduction Strategies for Opioid Use Disorder

This activity is for Pharmacy Technicians and is sponsored by Postgraduate Healthcare Education, LLC (PHE).
There has been no commercial support for this activity.


Bethany DiPaula, PharmD, BCPP
Director of Pharmacy, Springfield Hospital Center
Professor, University of Maryland School of Pharmacy
Springfield Hospital Center
Sykesville, MD


Bethany DiPaula, PharmD, BCPP hereby state that she has no relevant affiliation or financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose.

The following reviewer, Steven Kheloussi, PharmD, hereby states she has no relevant affiliation or financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose.

Susanne Batesko, RN, BSN, Robin Carrino, and L. Michael Posey, BSPharm, MA, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.


acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-18-068-H01-T

Credits: 2.0 hours (0.20 ceu)
Type of Activity: Knowledge
Media: Internet
Estimated time to complete activity: 120 minutes

Fee Information: $4.50

Release Date

November 30, 2018

Expiration Date

November 30, 2021


This accredited activity has been designed for pharmacy technicians.


During the period November 30, 2018, through November 30, 2021, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Grade Exam at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


To ensure that pharmacists and pharmacy technicians understand the concept of harm reduction as it relates to the management of opioid use disorder and, specifically, the role of naloxone in managing an opioid overdose.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  1. Explain the signs of an opioid overdose and identify patients that might be at risk for developing an opioid overdose
  2. Identify appropriate naloxone regimens (including route, dose, and dosing frequency) for the community management of an opioid overdose
  3. Cite relevant agent-related variables (adverse effects, pharmacokinetics, drug-drug interactions, monitoring parameters) and patient-related variables associated with naloxone for the community management of an opioid overdose
  4. Define the concept of harm reduction and describe how it relates to opioid use  disorder
  5. Summarize relevant opioid use disorder, naloxone, and harm reduction patient interaction using patient-centered language and identify when to refer to the pharmacist


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer:

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without an evaluation of their patients' conditions and current medications, including the identification of possible contraindications regarding the dangers of use and a review of any applicable manufacturer's product information, as well as a comparison with the recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.